Dermato-Onco2024 | Real-time surveillance with ctDNA in stage III BRAF-positive melanoma
Gabriele Roccuzzo
• 31 Oct 2024
Gabriele Roccuzzo, MD, University of Turin, Turin, Italy, shares results from a longitudinal study, which explored the predictive accuracy of circulating tumor DNA (ctDNA) for relapse risk in patients with stage III BRAF-positive cutaneous melanoma. The cohort consisted of 32 patients who received either immunotherapy or targeted therapy in adjuvant settings. A 12-month follow-up revealed that patients who expressed higher levels of ctDNA were correlated to a higher risk of relapse. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
